Enanta Pharmaceuticals
ENTA
108 hedge funds and large institutions have $139M invested in Enanta Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 43 reducing their positions, and 17 closing their positions.
4,444% more call options, than puts
Call options by funds: $409K | Put options by funds: $9K
36% more capital invested
Capital invested by funds: $103M → $139M (+$36.6M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.05% less ownership
Funds ownership: 87.32% → 86.28% (-1%)
2% less funds holding
Funds holding: 110 → 108 (-2)
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
21% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$3.15M |
| 2 |
Millennium Management
New York
|
+$672K |
| 3 |
BIG
Brooklyn Investment Group
Brooklyn,
New York
|
+$256K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$235K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$223K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.2M |
| 2 |
BlackRock
New York
|
-$1.03M |
| 3 |
D.E. Shaw & Co
New York
|
-$608K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$449K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$417K |
ENTA Hedge Fund Activity: Q2 2025 in Review
108 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q2 2025, worth a combined $139M — up 36% from $103M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ENTA and 15 opened new positions — a net loss of 2 holders — while 43 trimmed existing stakes and 34 added.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $3.15M. The largest seller was Morgan Stanley, cutting an estimated $1.2M.
- 108 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q2 2025, down from 110 in Q1 2025.
- Funds reported $139M of Enanta Pharmaceuticals stock for Q2 2025, up 36% quarter-over-quarter.
- 15 funds opened new Enanta Pharmaceuticals positions in Q2 2025 and 17 closed out, a net change of -2 holders.
- The largest Enanta Pharmaceuticals buyer in Q2 2025 was Janus Henderson Group, an estimated $3.15M added.
- The largest Enanta Pharmaceuticals seller in Q2 2025 was Morgan Stanley, an estimated $1.2M sold.
Based on aggregated 13F filings for Q2 2025.